Liu Yingxue, Zhang Xiaoyan, Gu Wenchao, Su Hui, Wang Xin, Wang Xu, Zhang Jiayu, Xu Midie, Sheng Weiqi
Department of Pathology, Fudan University Shanghai Cancer Center, Shanghai 200032, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai 200032, China; Institute of Pathology, Fudan University, Shanghai 200032, China.
Department of Diagnostic and Interventional Radiology, University of Tsukuba, Ibaraki, Japan.
J Adv Res. 2025 May;71:399-413. doi: 10.1016/j.jare.2024.05.031. Epub 2024 May 31.
BACKGROUND: Tumor metastasis represents a stepwise progression and stands as a principal determinant of unfavorable prognoses among cancer patients. Consequently, an in-depth exploration of its mechanisms holds paramount clinical significance. Cancer-associated fibroblasts (CAFs), constituting the most abundant stromal cell population within the tumor microenvironment (TME), have garnered robust evidence support for their pivotal regulatory roles in tumor metastasis. AIM OF REVIEW: This review systematically explores the roles of CAFs at eight critical stages of tumorigenic dissemination: 1) extracellular matrix (ECM) remodeling, 2) epithelial-mesenchymal transition (EMT), 3) angiogenesis, 4) tumor metabolism, 5) perivascular migration, 6) immune escape, 7) dormancy, and 8) premetastatic niche (PMN) formation. Additionally, we provide a compendium of extant strategies aimed at targeting CAFs in cancer therapy. KEY SCIENTIFIC CONCEPTS OF REVIEW: This review delineates a structured framework for the interplay between CAFs and tumor metastasis while furnishing insights for the potential therapeutic developments. It contributes to a deeper understanding of cancer metastasis within the TME, facilitating the utilization of CAF-targeting therapies in anti-metastatic approaches.
J Hematol Oncol. 2025-3-28
Int Immunopharmacol. 2024-12-25
Mol Cancer. 2021-12-1
J Exp Clin Cancer Res. 2024-12-19
Front Bioeng Biotechnol. 2025-8-12
Cancers (Basel). 2025-7-15
Technol Cancer Res Treat. 2025
Front Immunol. 2025-4-17
Front Immunol. 2025-4-1
Biofabrication. 2023-6-9